211 related articles for article (PubMed ID: 30308177)
21. Nanoparticles in the pharmaceutical industry and the use of supercritical fluid technologies for nanoparticle production.
Sheth P; Sandhu H; Singhal D; Malick W; Shah N; Kislalioglu MS
Curr Drug Deliv; 2012 May; 9(3):269-84. PubMed ID: 22283656
[TBL] [Abstract][Full Text] [Related]
22. A quality-by-design study for an immediate-release tablet platform: examining the relative impact of active pharmaceutical ingredient properties, processing methods, and excipient variability on drug product quality attributes.
Kushner J; Langdon BA; Hicks I; Song D; Li F; Kathiria L; Kane A; Ranade G; Agarwal K
J Pharm Sci; 2014 Feb; 103(2):527-38. PubMed ID: 24375069
[TBL] [Abstract][Full Text] [Related]
23. Continuous low-dose feeding of highly active pharmaceutical ingredients in hot-melt extrusion.
Llusa M; Mohr S; Baumgartner R; Paudel A; Koscher G; Khinast J
Drug Dev Ind Pharm; 2016 Aug; 42(8):1360-4. PubMed ID: 26755129
[TBL] [Abstract][Full Text] [Related]
24. Supercritical fluid particle design for poorly water-soluble drugs (review).
Sun Y
Curr Pharm Des; 2014; 20(3):349-68. PubMed ID: 23651403
[TBL] [Abstract][Full Text] [Related]
25. Comminution of ibuprofen to produce nano-particles for rapid dissolution.
Plakkot S; de Matas M; York P; Saunders M; Sulaiman B
Int J Pharm; 2011 Aug; 415(1-2):307-14. PubMed ID: 21683776
[TBL] [Abstract][Full Text] [Related]
26. Crystal and Particle Engineering Strategies for Improving Powder Compression and Flow Properties to Enable Continuous Tablet Manufacturing by Direct Compression.
Chattoraj S; Sun CC
J Pharm Sci; 2018 Apr; 107(4):968-974. PubMed ID: 29247737
[TBL] [Abstract][Full Text] [Related]
27. Functionalised particles using dry powder coating in pharmaceutical drug delivery: promises and challenges.
Dahmash EZ; Mohammed AR
Expert Opin Drug Deliv; 2015; 12(12):1867-79. PubMed ID: 26289674
[TBL] [Abstract][Full Text] [Related]
28. Pharmaceutical Applications of Electrospraying.
Nguyen DN; Clasen C; Van den Mooter G
J Pharm Sci; 2016 Sep; 105(9):2601-2620. PubMed ID: 27287515
[TBL] [Abstract][Full Text] [Related]
29. Improved dissolution behavior of lipophilic drugs by solid dispersions: the production process as starting point for formulation considerations.
Srinarong P; de Waard H; Frijlink HW; Hinrichs WL
Expert Opin Drug Deliv; 2011 Sep; 8(9):1121-40. PubMed ID: 21722000
[TBL] [Abstract][Full Text] [Related]
30. Understanding the effect of lactose particle size on the properties of DPI formulations using experimental design.
Guenette E; Barrett A; Kraus D; Brody R; Harding L; Magee G
Int J Pharm; 2009 Oct; 380(1-2):80-8. PubMed ID: 19596428
[TBL] [Abstract][Full Text] [Related]
31. Comparison of Rheological and Sedimentation Behavior of Commercially Available Suspending Vehicles for Oral Pharmaceutical Preparations.
Visser JC; Ten Seldam IEJ; van der Linden IJ; Hinrichs WLJ; Veenendaal RFH; Dijkers ECF; Woerdenbag HJ
Int J Pharm Compd; 2018; 22(3):247-251. PubMed ID: 29878892
[TBL] [Abstract][Full Text] [Related]
32. Phase transformation considerations during process development and manufacture of solid oral dosage forms.
Zhang GG; Law D; Schmitt EA; Qiu Y
Adv Drug Deliv Rev; 2004 Feb; 56(3):371-90. PubMed ID: 14962587
[TBL] [Abstract][Full Text] [Related]
33. On the relationship of inter-particle cohesiveness and bulk powder behavior: Flowability of pharmaceutical powders.
Capece M; Silva KR; Sunkara D; Strong J; Gao P
Int J Pharm; 2016 Sep; 511(1):178-189. PubMed ID: 27353729
[TBL] [Abstract][Full Text] [Related]
34. Spray freezing into liquid (SFL) particle engineering technology to enhance dissolution of poorly water soluble drugs: organic solvent versus organic/aqueous co-solvent systems.
Hu J; Johnston KP; Williams RO
Eur J Pharm Sci; 2003 Nov; 20(3):295-303. PubMed ID: 14592695
[TBL] [Abstract][Full Text] [Related]
35. A novel oil-based suspension of a micro-environmental, pH-modifying solid dispersion for parenteral delivery: Formulation and stability evaluation.
Zhang S; Wan Q; Xu X; Xing Y; Ding J; Yang S; Sun W; Lu M; Pan B
Colloids Surf B Biointerfaces; 2019 Jul; 179():382-392. PubMed ID: 30999117
[TBL] [Abstract][Full Text] [Related]
36. Novel powder formulations for controlled delivery of poorly soluble anticancer drug: application and investigation of TPGS and PEG in spray-dried particulate system.
Mu L; Teo MM; Ning HZ; Tan CS; Feng SS
J Control Release; 2005 Apr; 103(3):565-75. PubMed ID: 15820404
[TBL] [Abstract][Full Text] [Related]
37. Development of novel microprecipitated bulk powder (MBP) technology for manufacturing stable amorphous formulations of poorly soluble drugs.
Shah N; Sandhu H; Phuapradit W; Pinal R; Iyer R; Albano A; Chatterji A; Anand S; Choi DS; Tang K; Tian H; Chokshi H; Singhal D; Malick W
Int J Pharm; 2012 Nov; 438(1-2):53-60. PubMed ID: 22974525
[TBL] [Abstract][Full Text] [Related]
38. Development and characterization of a scalable controlled precipitation process to enhance the dissolution of poorly water-soluble drugs.
Rogers TL; Gillespie IB; Hitt JE; Fransen KL; Crowl CA; Tucker CJ; Kupperblatt GB; Becker JN; Wilson DL; Todd C; Broomall CF; Evans JC; Elder EJ
Pharm Res; 2004 Nov; 21(11):2048-57. PubMed ID: 15587927
[TBL] [Abstract][Full Text] [Related]
39. Solution-based particle formation of pharmaceutical powders by supercritical or compressed fluid CO2 and cryogenic spray-freezing technologies.
Rogers TL; Johnston KP; Williams RO
Drug Dev Ind Pharm; 2001 Nov; 27(10):1003-15. PubMed ID: 11794803
[TBL] [Abstract][Full Text] [Related]
40. On-Demand Manufacturing of Direct Compressible Tablets: Can Formulation Be Simplified?
Azad MA; Osorio JG; Wang A; Klee DM; Eccles ME; Grela E; Sloan R; Hammersmith G; Rapp K; Brancazio D; Myerson AS
Pharm Res; 2019 Oct; 36(12):167. PubMed ID: 31650274
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
